Bedrijfsoverzicht
PepGen Inc. is a clinical-stage biotechnology entity dedicated to the development of oligonucleotide therapeutics specifically designed to treat severe neuromuscular and neurologic diseases within the United States market. The company operates within the healthcare sector, specifically the biotechnology industry, a domain characterized by high research and development expenditures and significant regulatory scrutiny for bringing novel treatments to patients. PepGen Inc. currently maintains a market capitalization of $113.35M and employs a workforce of 56 individuals to advance its proprietary pipeline, including the EDO peptide-conjugated PMO known as PGN-EDODM1 which is currently in Phase 2 clinical trials. The market capitalization of $113.35M indicates that the company holds a relatively small position within the broader biotechnology landscape, suggesting it is an early-stage venture that has not yet achieved the revenue scale typical of established pharmaceutical firms, while the absence of reported annual revenue highlights its status as a pre-commercial entity reliant on external capital and future clinical success.
Financiële gezondheid
PepGen Inc. reports no reported annual revenue over the trailing twelve months, a net income of $-89,655,000, and an EBITDA of $-92,215,000, illustrating a substantial gap between revenue and profitability that reveals a cost structure dominated by research and development expenses rather than commercial sales. The company generates free cash flow of $-49,845,500, which indicates a consumption of cash reserves to fund operations and clinical trials, thereby limiting current financial flexibility and necessitating ongoing access to capital markets. All three margin metrics are recorded at 0.0%, with gross margin, operating margin, and profit margin all showing zero profitability, which signifies that the company has not yet generated enough revenue to cover its direct costs or operating expenses to achieve a positive margin. In terms of liquidity and leverage, PepGen Inc. holds cash totaling $148.46M against total debt of $17.00M, resulting in a debt-to-equity ratio of 11.53, which suggests a balance sheet that is currently leveraged but supported by a significant cash buffer despite the negative equity position. The current ratio stands at 11.94, indicating a robust ability to cover short-term liabilities with short-term assets, although this high ratio is likely inflated by the large cash balance relative to minimal debt obligations. Furthermore, the return on equity is -67.4% and the return on assets is -36.0%, metrics that reveal that management has not yet achieved effective profitability on the capital invested or the assets utilized, reflecting the inherent financial losses typical of clinical-stage biotechnology companies before product commercialization.
Waarderingsbeoordeling
The trailing P/E ratio is N/A due to the lack of earnings, while the forward P/E is listed as -1.41, a negative figure that implies the market does not expect immediate earnings normalization and reflects the speculative nature of valuing a company with no current profits. The price-to-book ratio is 0.77, indicating that the stock is trading at a discount to its book value, which can suggest either a market undervaluation of the company's assets or a lack of confidence in the ability to convert those assets into profitable ventures. Alternative valuation metrics such as the price-to-sales ratio, which is N/A, and the EV/EBITDA of 0.20, provide different perspectives; the low EV/EBITDA of 0.20 suggests a valuation based on enterprise value relative to earnings before interest, taxes, depreciation, and amortization that is depressed due to the significant cash position and negative earnings. The stock has a 52-week high of $7.80 and a 52-week low of $1.01, meaning the current price sits within a wide trading range that reflects high volatility and significant uncertainty regarding the company's future trajectory. The beta value is 2.34, which indicates that the stock price is expected to be significantly more volatile than the broader market, moving with greater intensity in response to sector-specific news or general market fluctuations.
Growth & Income
Revenue growth year-over-year is N/A and earnings growth year-over-year is N/A, as the company has not yet achieved commercial sales, meaning there is no historical data to compare earnings growth against revenue growth at this stage of the business lifecycle. PepGen Inc. does not pay a dividend, with a dividend yield of N/A and a payout ratio of 0.0%, which implies that the company reinvests all available capital, including its substantial cash reserves, back into research and development activities rather than distributing income to shareholders. The overall growth and income profile is characterized by a complete absence of current income generation, with the company relying entirely on future clinical trial successes and potential regulatory approvals to transition from a cash-consuming entity to a revenue-producing one.